Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens

Rahmah Rasat, E. A. Espiner, G. D. Abbott

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aim. To assess outcome (final height and sexual maturation), growth patterns and blood pressure in 16 children with congenital adrenal hyperplasia treated at one institution over a 30 year period. Methods. Growth patterns and maturation were determined by retrospective review (median follow up period 14 years). Dose adjustment of corticosteroid replacement treatment, sufficient to maintain normal levels of adrenal precursor secretion, was determined using assays of urinary pregnanetriol excretion (up to 1975) or early morning measurements of plasma 17 hydroxy progesterone and plasma renin activity at intervals of 4-6 months. Results. In 7 of 15 patients the growth pattern during infancy was retarded - 13 not exceeding the population mean. Catchup growth as steroid dose fell with age was not usually observed. In boys, height potential was further compromised by a significant reduction in growth velocity during puberty. None of nine pateints evaluated at final height had attained the target height. During the first year of life, plasma renin activity was suppressed below the lower than normal levels of plasma renin activity in childhood, most children were normotensive. Conclusions. Avoiding salt depletion in infancy and excessive androgen secretion during childhood do not ensure normal growth patterns or normal final height. Impaired final height in congenital adrenal hyperplasia is more likely to be due to over treatment, particularly in infancy when lower doses of corticosteroids may improve height prognosis.

Original languageEnglish
Pages (from-to)311-314
Number of pages4
JournalNew Zealand Medical Journal
Volume108
Issue number1005
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Congenital Adrenal Hyperplasia
Growth
Renin
Adrenal Cortex Hormones
Pregnanetriol
Therapeutics
Sexual Maturation
Puberty
Androgens
Progesterone
Salts
Steroids
Blood Pressure
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens. / Rasat, Rahmah; Espiner, E. A.; Abbott, G. D.

In: New Zealand Medical Journal, Vol. 108, No. 1005, 1995, p. 311-314.

Research output: Contribution to journalArticle

Rasat, Rahmah ; Espiner, E. A. ; Abbott, G. D. / Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens. In: New Zealand Medical Journal. 1995 ; Vol. 108, No. 1005. pp. 311-314.
@article{46df96213be842ca8e52e5a51be64023,
title = "Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens",
abstract = "Aim. To assess outcome (final height and sexual maturation), growth patterns and blood pressure in 16 children with congenital adrenal hyperplasia treated at one institution over a 30 year period. Methods. Growth patterns and maturation were determined by retrospective review (median follow up period 14 years). Dose adjustment of corticosteroid replacement treatment, sufficient to maintain normal levels of adrenal precursor secretion, was determined using assays of urinary pregnanetriol excretion (up to 1975) or early morning measurements of plasma 17 hydroxy progesterone and plasma renin activity at intervals of 4-6 months. Results. In 7 of 15 patients the growth pattern during infancy was retarded - 13 not exceeding the population mean. Catchup growth as steroid dose fell with age was not usually observed. In boys, height potential was further compromised by a significant reduction in growth velocity during puberty. None of nine pateints evaluated at final height had attained the target height. During the first year of life, plasma renin activity was suppressed below the lower than normal levels of plasma renin activity in childhood, most children were normotensive. Conclusions. Avoiding salt depletion in infancy and excessive androgen secretion during childhood do not ensure normal growth patterns or normal final height. Impaired final height in congenital adrenal hyperplasia is more likely to be due to over treatment, particularly in infancy when lower doses of corticosteroids may improve height prognosis.",
author = "Rahmah Rasat and Espiner, {E. A.} and Abbott, {G. D.}",
year = "1995",
language = "English",
volume = "108",
pages = "311--314",
journal = "New Zealand Medical Journal",
issn = "0028-8446",
publisher = "New Zealand Medical Association",
number = "1005",

}

TY - JOUR

T1 - Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens

AU - Rasat, Rahmah

AU - Espiner, E. A.

AU - Abbott, G. D.

PY - 1995

Y1 - 1995

N2 - Aim. To assess outcome (final height and sexual maturation), growth patterns and blood pressure in 16 children with congenital adrenal hyperplasia treated at one institution over a 30 year period. Methods. Growth patterns and maturation were determined by retrospective review (median follow up period 14 years). Dose adjustment of corticosteroid replacement treatment, sufficient to maintain normal levels of adrenal precursor secretion, was determined using assays of urinary pregnanetriol excretion (up to 1975) or early morning measurements of plasma 17 hydroxy progesterone and plasma renin activity at intervals of 4-6 months. Results. In 7 of 15 patients the growth pattern during infancy was retarded - 13 not exceeding the population mean. Catchup growth as steroid dose fell with age was not usually observed. In boys, height potential was further compromised by a significant reduction in growth velocity during puberty. None of nine pateints evaluated at final height had attained the target height. During the first year of life, plasma renin activity was suppressed below the lower than normal levels of plasma renin activity in childhood, most children were normotensive. Conclusions. Avoiding salt depletion in infancy and excessive androgen secretion during childhood do not ensure normal growth patterns or normal final height. Impaired final height in congenital adrenal hyperplasia is more likely to be due to over treatment, particularly in infancy when lower doses of corticosteroids may improve height prognosis.

AB - Aim. To assess outcome (final height and sexual maturation), growth patterns and blood pressure in 16 children with congenital adrenal hyperplasia treated at one institution over a 30 year period. Methods. Growth patterns and maturation were determined by retrospective review (median follow up period 14 years). Dose adjustment of corticosteroid replacement treatment, sufficient to maintain normal levels of adrenal precursor secretion, was determined using assays of urinary pregnanetriol excretion (up to 1975) or early morning measurements of plasma 17 hydroxy progesterone and plasma renin activity at intervals of 4-6 months. Results. In 7 of 15 patients the growth pattern during infancy was retarded - 13 not exceeding the population mean. Catchup growth as steroid dose fell with age was not usually observed. In boys, height potential was further compromised by a significant reduction in growth velocity during puberty. None of nine pateints evaluated at final height had attained the target height. During the first year of life, plasma renin activity was suppressed below the lower than normal levels of plasma renin activity in childhood, most children were normotensive. Conclusions. Avoiding salt depletion in infancy and excessive androgen secretion during childhood do not ensure normal growth patterns or normal final height. Impaired final height in congenital adrenal hyperplasia is more likely to be due to over treatment, particularly in infancy when lower doses of corticosteroids may improve height prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0029129247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029129247&partnerID=8YFLogxK

M3 - Article

C2 - 7644165

AN - SCOPUS:0029129247

VL - 108

SP - 311

EP - 314

JO - New Zealand Medical Journal

JF - New Zealand Medical Journal

SN - 0028-8446

IS - 1005

ER -